Please login to the form below

Not currently logged in
Email:
Password:

Vosevi

This page shows the latest Vosevi news and features for those working in and with pharma, biotech and healthcare.

Gilead wins European approval for triple hep C combination Vosevi

Gilead wins European approval for triple hep C combination Vosevi

Gilead wins European approval for triple hep C combination Vosevi. The treatment brings together sofosbuvir, velpatasvir and voxilaprevir. ... The results show that 97% of patients on Vosevi achieved the primary efficacy endpoint of a sustained viral

Latest news

  • Gilead gets OK for three-in-one hep C therapy in US Gilead gets OK for three-in-one hep C therapy in US

    The US FDA has approved Gilead Sciences' triple drug therapy Vosevi to treat hepatitis C Virus (HCV) as a back-up therapy for patients who can't eliminate the virus with ... The FDA has cleared the new product for all the most common HCV genotypes (1-6)

  • Samsung Bioepis wins CHMP nod for second Humira biosimilar Samsung Bioepis wins CHMP nod for second Humira biosimilar

    virus (infection) - AbbVie's Maviret (glecaprevir/pibrentasvir) and Gilead's Vosevi (sofosbuvir/velpatasvir/voxilaprevir). ... The CHMP notes that "both Maviret and Vosevi are active against all genotypes of the virus and with some differences between

More from news
Approximately 2 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...
AZ Campus
AstraZeneca: building a new ‘open innovation’ pharma company
The construction of its new HQ has suffered some serious delays, but new R&D and commercial success are lifting AstraZeneca’s prospects...
Erik Nordkamp
In conversation with Pfizer’s Erik Nordkamp
Pfizer’s UK general manager talks to PME about the NHS at 70, the potential of pharma partnerships and some lessons from Europe...

Infographics